Profound Medical (TSE:PRN) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Profound Medical Corp. is set to announce its Q2 2024 financial results on August 8, followed by a conference call to discuss the company’s business developments. Investors can tune into the live call via the company’s website or through a provided registration link. Profound is known for its innovative, incision-free therapies for tissue ablation, including TULSA-PRO for prostate issues and Sonalleve for uterine fibroids and bone metastases pain relief.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
